Valuation Trading Multiples & Precedent Transactions: Targeted Oncology Biopharma Companies
Valuation benchmarks for Targeted Oncology Biopharma Companies. Access public trading comps, EV/EBITDA acquisition multiples, and private market data for pitch books and valuation analysis.
1.1 - Targeted Oncology Biopharma Companies Market Context & Valuation Drivers
Companies in this trading comparables group develop and commercialize precision oncology therapeutics, including targeted small molecules, biologics, radiopharmaceuticals, and T‑cell receptor therapies. Business models center on proprietary drug pipelines, regulatory approvals, and commercialization via direct sales and partnerships. They are comparable due to oncology focus, trial-driven milestones, similar revenue mix (product sales and licensing), R&D intensity, and risk-return profiles tied to clinical and market uptake.
Typical capabilities span discovery and preclinical research; development of targeted kinase inhibitors, EGFR therapies, monoclonal and bispecific antibodies; radiopharmaceutical imaging and theranostics; TCR-based immunotherapies; GMP manufacturing and supply chain for biologics and small molecules; companion diagnostics and patient selection; global clinical trials and regulatory submissions; and commercialization through specialty oncology sales, medical affairs, and market access, often complemented by licensing, co-development, and regional distribution partnerships.
Primary customers include hospitals and cancer centers, oncologists and healthcare providers, and specialty pharmacies and distributors, with payers influencing adoption through reimbursement. Key valuation benchmarks include revenue growth from marketed products, gross margins by modality, pipeline breadth and phase mix, approval and launch timelines, geographic expansion, and partnership income. Analysts also assess R&D spend efficiency, pricing durability, and patient uptake to gauge sustainability of cash flows.
2. Valuation Analysis: Public Trading Comps & Multiples for Targeted Oncology Biopharma Companies companies
2.1 - Public Peer Groups & Median Valuation Multiples for Targeted Oncology Biopharma Companies sector
Comparable group 1: Targeted Oncology Biopharma Companies
Telix Pharmaceuticals
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of theranostic products aimed at addressing oncology, specializing in developing targeted diagnostic and therapeutic solutions for prostate, kidney, brain, and musculoskeletal cancers, leveraging advanced radio-pharmaceutical technologies.
- Key Products:
- Prostate Cancer Imaging: Offers Illuccix® which utilizes gallium-68 for effective prostate cancer PET imaging
- Radiopharmaceuticals: Develops and commercializes radiopharmaceutical solutions for the diagnosis and treatment of multiple cancer types
- Clinical Trials: Conducts extensive clinical trials to validate the safety and efficacy of diagnostic and therapeutic agents.
Shanghai Allist
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative pharmaceutical solutions, specializing in cancer treatment, focusing on discovering, developing, manufacturing, and commercializing new medicines.
- Key Products:
- Innovative Medicines: Development and commercialization of drugs for cancer treatment focusing on lung cancer
- Research and Development: Continuous efforts in developing new pharmaceutical therapies.